Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced participation in a fireside chat at the JMP Securities Life Sciences Conference on June 15-16, 2022, held at the Lotte New York Palace. The chat is scheduled for 3:30 p.m. Eastern Time on June 15. Investors can access the live and archived presentation via the provided webcast link. The company focuses on developing therapies for rare endocrine diseases, with candidates like paltusotine in Phase 3 development for acromegaly.

SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in person in a fireside chat at the annual JMP Securities Life Sciences Conference, which is being held at the Lotte New York Palace on June 15-16, 2022.

Details of the fireside chat are as follows:
Date:	Wednesday, June 15, 2022
Time:	3:30 p.m. Eastern Time
Webcast Link:	https://wsw.com/webcast/jmp54/crnx/1693872

In addition, the live and archived presentation will be accessible on the Events & Presentations page in the Investors section on the Company’s website.

About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Currently, paltusotine is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in Phase 1 clinical studies for CRN04777, a somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism and CRN04894, an ACTH antagonist for the treatment of congenital adrenal hyperplasia, Cushing’s disease and other diseases of excess ACTH. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts.

Contacts:
Chas Schultz
VP, IR & Corporate Communications
cschultz@crinetics.com
(858) 450-6464

Investors / Media:
Corey Davis
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577

Aline Sherwood
Scienta Communications
asherwood@scientapr.com
(312) 238-8957

FAQ

When is Crinetics Pharmaceuticals' fireside chat at the JMP Securities Life Sciences Conference?

Crinetics Pharmaceuticals' fireside chat is on June 15, 2022, at 3:30 p.m. Eastern Time.

Where can I watch the Crinetics Pharmaceuticals' conference presentation?

The presentation can be accessed live and in archive via the webcast link.

What is Crinetics Pharmaceuticals known for?

Crinetics Pharmaceuticals specializes in developing therapies for rare endocrine diseases and endocrine-related tumors.

Which drug candidates are in development by Crinetics Pharmaceuticals?

Crinetics is developing paltusotine in Phase 3 for acromegaly and has other candidates like CRN04777 and CRN04894.

What is the ticker symbol for Crinetics Pharmaceuticals?

The ticker symbol for Crinetics Pharmaceuticals is CRNX.